Synonym
Hexafluoro; B 1673141; B-1673141; B1673141;
IUPAC/Chemical Name
Bistrifluoromethyl-bis-(4-hydroxy-3-allylphenyl) methane
InChi Key
QGHDLJAZIIFENW-UHFFFAOYSA-N
InChi Code
InChI=1S/C21H18F6O2/c1-3-5-13-11-15(7-9-17(13)28)19(20(22,23)24,21(25,26)27)16-8-10-18(29)14(12-16)6-4-2/h3-4,7-12,28-29H,1-2,5-6H2
SMILES Code
C=CCC1=CC(C(C(F)(F)F)(C(F)(F)F)C2=CC=C(O)C(CC=C)=C2)=CC=C1O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
416.36
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Lin H, Song P, Zhao Y, Xue LJ, Liu Y, Chu CQ. Targeting Th17 Cells with Small Molecules and Small Interference RNA. Mediators Inflamm. 2015;2015:290657. doi: 10.1155/2015/290657. Epub 2015 Dec 17. Review. PubMed PMID: 26792955; PubMed Central PMCID: PMC4697089.
2: Pazos G, Rivadulla ML, Pérez-García X, Gandara Z, Pérez M. Gemini analogs of vitamin D. Curr Top Med Chem. 2014;14(21):2388-97. Review. PubMed PMID: 25486935.
3: Mazzaferro S, Pasquali M, Conte C, Mandanici G, Muci M, Lavini R. Vitamin D receptor activators. Int J Artif Organs. 2009 Feb;32(2):101-7. Review. PubMed PMID: 19363782.
4: Morii H. [Falecalcitriol as a new therapeutic agent for secondary hyperparathyroidism]. Clin Calcium. 2005 Jan;15(1):29-33. Review. Japanese. PubMed PMID: 15632470.
5: Miwa N, Akiba T. [The trend in the development of the active vitamin D3 and its analogues]. Nihon Rinsho. 2004 May;62 Suppl 5:364-7. Review. Japanese. PubMed PMID: 15197946.
6: Ohtsuka N, Urayama K. [Pharmacological action and clinical effects of falecalcitriol, a highly potent derivative of active vitamin D3]. Nihon Yakurigaku Zasshi. 2002 Dec;120(6):427-36. Review. Japanese. PubMed PMID: 12528474.
7: Adorini L, Penna G, Giarratana N, Uskokovic M. Tolerogenic dendritic cells induced by vitamin D receptor ligands enhance regulatory T cells inhibiting allograft rejection and autoimmune diseases. J Cell Biochem. 2003 Feb 1;88(2):227-33. Review. PubMed PMID: 12520519.
8: Uskokovic MR, Norman AW, Manchand PS, Studzinski GP, Campbell MJ, Koeffler HP, Takeuchi A, Siu-Caldera ML, Rao DS, Reddy GS. Highly active analogs of 1alpha,25-dihydroxyvitamin D(3) that resist metabolism through C-24 oxidation and C-3 epimerization pathways. Steroids. 2001 Mar-May;66(3-5):463-71. Review. PubMed PMID: 11179755.
9: Tohma H. [Development of novel oxidation reactions using hypervalent iodine reagents and their application to total synthesis of biologically active natural products]. Yakugaku Zasshi. 2000 Jul;120(7):620-9. Review. Japanese. PubMed PMID: 10920716.
